Takeda Pharmaceutical Company Limited vs Perrigo Company plc: A Gross Profit Performance Breakdown

Takeda vs. Perrigo: A Decade of Gross Profit Dynamics

__timestampPerrigo Company plcTakeda Pharmaceutical Company Limited
Wednesday, January 1, 201414477000001256834000000
Thursday, January 1, 201517124000001271973000000
Friday, January 1, 201620518000001173296000000
Sunday, January 1, 201719795000001274610000000
Monday, January 1, 201818315000001437534000000
Tuesday, January 1, 201917733000002201424000000
Wednesday, January 1, 202018152000002203504000000
Friday, January 1, 202114162000002462160000000
Saturday, January 1, 202214554000002783406000000
Sunday, January 1, 202316804000002832257000000
Monday, January 1, 20242832257000000
Loading chart...

Unleashing insights

A Tale of Two Giants: Takeda vs. Perrigo

In the ever-evolving pharmaceutical landscape, Takeda Pharmaceutical Company Limited and Perrigo Company plc stand as titans, each with a unique trajectory in gross profit performance. From 2014 to 2023, Takeda's gross profit surged by approximately 125%, reaching a staggering 2.83 trillion yen in 2023. This growth reflects Takeda's strategic acquisitions and robust product pipeline.

Conversely, Perrigo's journey has been more volatile. Despite a peak in 2016, Perrigo's gross profit saw fluctuations, ending 2023 with a modest 16% increase from 2014. This reflects the challenges faced in the competitive over-the-counter market.

The data reveals a compelling narrative of growth and resilience, with Takeda's consistent upward trend contrasting Perrigo's more erratic path. As the pharmaceutical industry continues to evolve, these insights offer a glimpse into the strategic maneuvers of two industry leaders.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025